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Abstract
Background: The aim of this study is to evaluate the association between acute serum creatinine
changes in acute renal failure (ARF), before specialized treatment begins, and in-hospital mortality,
recovery of renal function, and overall mortality at 6 months, on an equal degree of ARF severity,
using the RIFLE criteria, and comorbid illnesses.
Methods: Prospective cohort study of 1008 consecutive patients who had been diagnosed as
having ARF, and had been admitted in an university-affiliated hospital over 10 years. Demographic,
clinical information and outcomes were measured. After that, 646 patients who had presented
enough increment in serum creatinine to qualify for the RIFLE criteria were included for
subsequent analysis. The population was divided into two groups using the median serum creatinine
change (101%) as the cut-off value. Multivariate non-conditional logistic and linear regression
models were used.
Results: A ≥ 101% increment of creatinine respect to its baseline before nephrology consultation
was associated with significant increase of in-hospital mortality (35.6% vs. 22.6%, p < 0.001), with
an adjusted odds ratio of 1.81 (95% CI: 1.08–3.03). Patients who required continuous renal
replacement therapy in the ≥ 101% increment group presented a higher increase of in-hospital
mortality (62.7% vs 46.4%, p = 0.048), with an adjusted odds ratio of 2.66 (95% CI: 1.00–7.21).
Patients in the ≥ 101% increment group had a higher mean serum creatinine level with respect to
their baseline level (114.72% vs. 37.96%) at hospital discharge. This was an adjusted 48.92% (95%
CI: 13.05–84.79) more serum creatinine than in the < 101% increment group.
Conclusion: In this cohort, patients who had presented an increment in serum level of creatinine
of ≥ 101% with respect to basal values, at the time of nephrology consultation, had increased
mortality rates and were discharged from hospital with a more deteriorated renal function than
those with similar Liano scoring and the same RIFLE classes, but with a < 101% increment. This
finding may provide more information about the factors involved in the prognosis of ARF.
Furthermore, the calculation of relative serum creatinine increase could be used as a practical tool
to identify those patients at risk, and that would benefit from an intensive therapy.
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Acute renal failure (ARF) is a life threatening illness with
a high mortality despite advances in supportive care [1-
14]. Although there is a strong and direct relation between
multiorgan failure and in-hospital mortality, severity of
illness does not explain the variation in outcomes among
patients with acute renal failure [5,9,10]. There is an
increased cost in terms of patient prognosis, financial and
clinical management. In a study, 30% of patients did not
recover completely their renal function [15] and, in other
studies, progression to chronic renal failure in many
patients is suggested [9,16]. In regard to these concerns,
prompt recognition and early consultation with a neph-
rologist have been postulated to improve the outcome of
patients with acute renal failure [7,11,12,17]. Neverthe-
less, the published evidence is scarce.
The absence of a consensus definition of ARF has made
research about ARF difficult [6,18,19]. Recently, the Acute
Dialysis Quality Initiative (ADQI) published a uniformed
definition called the RIFLE (Risk, Injury, Failure, Loss, End
Stage) criteria [20]. The RIFLE criteria has been adopted by
the Acute Kidney Injury Network (AKIN) [6].
Diagnosis of ARF based upon changes in serum creatinine
may be delayed due to the fact that, in the non-steady-
state conditions of ARF, as GFR falls creatinine secretion is
increased [11]. Large changes in GFR are initially mani-
fested as small quantitative changes in serum creatinine in
the first 24–48 hours after renal injury [11]. After these
one or two days, the degree of serum creatinine changes
will reflect the change in GFR. Finally, the serum creati-
nine is stabilized, and that takes about 7 days [11,20].
Therefore, it is almost impossible to exactly determine the
onset of the ARF; and also calculating the exact time
lapsed until the nephrology consultation. However, meas-
uring serum creatinine level is a practical approach for dis-
covering short-term alteration in renal function, despite
its limitations, because it is readily used in clinical practice
and it is specific for renal function [20,21]. In patients
with stable renal function, those levels are constant, with
a daily variability of 8% [22,23], so increasing levels
might suggest the first stage of ARF.
We conducted this study to identify and quantify a corre-
lation between acute serum creatinine changes in ARF,
measuring them at the time of nephrology consultation,
and mortality and recovery of renal function. We hypoth-
esized that, at the same levels of severity of renal and
comorbid illnesses, the higher the acute serum creatinine
reached with respect to its baseline, before the nephrolo-
gist first began to treat the patient, the worse the outcome
will be.
Methods
Study population
The University Hospital of Navarra is a tertiary care aca-
demic teaching medical center with 400 beds in the city of
Pamplona, Spain. After hospital ethics committe
approval, a cohort of 1008 consecutive patients who had
been diagnosed as having acute renal failure, and had
been admitted in our hospital between 1996 and 2006,
was prospectively entered in a computerized database.
Explicit patient consent was not required by the hospital
ethics committee due to the observational nature of the
study, and because collecting the data was a part of our
academical-hospital routine work. Patients' anonymity
was always strictly preserved. We restricted our analysis to
patients who had enough increase of serum creatinine
during their admission to fulfill the RIFLE criteria for ARF
[20], and were older than 16 years. Three hundred and six
patients did not fulfill the RIFLE serum creatinine criteria
nor presented oliguria during their stay. Forty-nine
patients presented oliguria, but did not have substantial
increase of creatinine. Seven patients were younger than
16 years. Finally, 646 patients were included for subse-
quent analysis.
Definition of the variables
ARF was defined and diagnosed if patients had showed
substantial increment in serum creatinine during their
admission to qualify for the RIFLE criteria. After that,
patients were classified to the maximum RIFLE class
according to the peak creatinine (the highest) reached
during their hospital stay. On the contrary, we could not
collect full information for urine output, so we were not
able to classify the patients by that RIFLE criteria. For
patients without chronic renal failure reported, the base-
line creatinine was calculated using the Modification of
Diet in Renal Disease (MDRD) equation [24], as recom-
mended by the ADQI workgroup [20], assuming a
glomerular filtration rate of 75 ml/minute/1,73 m2. For
patients with a history of renal failure the baseline creati-
nine was defined as the one measured at hospital admis-
sion [4]. The term community-acquired ARF was used
when the patient had presented ARF on admission to the
hospital.
Demographic data, etiology of acute renal failure, comor-
bid conditions, severity of illness, and laboratory data
were all prospectively collected. The difference between
serum creatinine value at time when nephrologist first saw
the case and baseline value was calculated and expressed
as a percentage: Creatinine change (%) = [(creatinine
when nephrologist saw the case - basal creatinine)/basal
creatinine] * 100. Severity of illness was measured
through Liano score (0.032*age in decades - 0.086*male
gender - 0.109*nephrotoxic + 0.109*oliguria +
0.116*hypotension + 0.122*jaundice + 0.150*coma -Page 2 of 9
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0.210) [21], Karnofsky score at home [25], and prior food
intake were also determined and computed at that point.
The patient's clinical status and treatment ARF were
recorded daily. Serum creatinine at hospital discharge was
recorded as a measure of recovery of renal function; the
difference between this value and the baseline value was
calculated and expressed in percentage: Creatinine change
(%) = [(creatinine at hospital discharge - basal creati-
nine)/basal creatinine] * 100. Food intake was defined as
previous caloric ingestion, and this was classified as
appropriate when it was optimal, light malnutrition when
it had been inappropriate less than three days, moderate
malnutrition when it had been inappropriate between
three and seven days, and severe malnutrition when it had
been inappropriate for more than seven days. We fol-
lowed up the patients after they were discharged from
hospital to study the mortality at 6 months from the
beginning of nephrology consultation.
Serum creatinine concentration was measured using the
kinetic Jaffe assay.
In our hospital, when renal function is impaired, nephrol-
ogy consulation can be requested, no matter in which hos-
pital ward the patient stays. A nephrologist is always the
only physician who provides a renal replacement therapy,
according to a strict protocol. However, opinion from
other medical departments involved in the patient's care
is always sought. In this study, all patients were treated
after the consultation by the same nephrologist, and all
the data were gathered by the same observer.
The primary endpoints were in-hospital mortality and
recovery of renal function at hospital discharge, following
the recommendations from the ADQI [26]. The secondary
endpoint was overall mortality at 6 months.
Statistical analysis
The increase in the percentage of creatinine reached before
the nephrologist first saw the case was considered as the
main exposure variable. The patients were divided into
two groups using the median (101%) as the cut-off value.
In addition, this cut-off point was the most optimal point
from a ROC analysis. We obtained one below the median
(group 1 or < 101% increment, hereafter), and one above
the median (group 2 or ≥ 101% increment, hereafter).
Non-conditional logistic regression models were fitted to
assess the relationship between the increase of percentage
in creatinine and the risk of in-hospital mortality. Odds
ratios (OR) and their 95% confidence intervals (CI) were
calculated considering the < 101% increment group as the
reference category. The OR represents an estimation of rel-
ative risks of death during the inpatient stay.
In addition, linear regression models were used to assess
the association between the increment of creatinine at
time when nephrologists saw the case (exposure), and the
recovery of renal function considering the increase in the
percentage of creatinine at hospital discharge with respect
to the baseline values (outcome). After excluding inhospi-
tal dead patients, we estimated the regression coefficient
and their 95% CI for the larger increment group compared
to the lesser increment group considered as the reference
category. This coefficient represents the absolute differ-
ence in creatinine increment at hospital discharge
between the ≥ 101% increment group and the < 101%
increment group.
In both non-conditional logistic regression and linear
regression, we fitted a crude model (univariate, i.e., with-
out any adjustment), an age and gender model, and a
multivariate-adjusted model including the following vari-
ables: Liano scoring, Karnofsky scoring, prior food intake,
chronic renal failure, diabetes, treatment of acute renal
failure, causes of acute renal failures, community-
acquired acute renal failure, basal hemoglobin, basal
serum albumin, and RIFLE classes selected by the descrip-
tive univariate analysis of potential confounders with a p
value less than 0.10. The Liano scoring includes in its
equation the variables for nephrotoxicity, oliguria, hypo-
tension, jaundice, mental status, and assisted respiration.
Continuous variables were expressed as medians (and
interquartile ranges), and compared using Mann-Whitney
U test. Categorical variables were expressed as proportions
and compared with the Chi-squared test. We evaluated all
first-order multiplicative interactions (effect modifica-
tions) through product terms.
Overall survival at 6 months across groups was analyzed
using the Kaplan-Meier methods, and differences between
groups were tested using the log-rank test. The time of ori-
gin was the date when the nephrology consultation
started. The event defined was death whereas those cases
alive at the end of follow-up and those lost to follow-up
were censored at their last observation.
All p values presented are two tailed, p < 0.05 was consid-
ered statistically significant. Statistical analyses were con-
ducted using SPSS v.12.0.1 (SPSS Inc., Chicago, IL, USA).
Results
Six hundred and forty-six patients were evaluated, among
them one hundred and eighty-eight died in-hospital. The
demographics and baseline clinical characteristics are
shown in Table 1. Subjects in the ≥ 101% increment of
creatinine group were more likely to be female (p = 0.01),
had impaired prior food intake (p = 0.02), and required
more renal replacement therapy (p < 0.001). The ≥ 101%
increment of creatinine group was associated with highPage 3 of 9
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worse Karnofsky scoring (p = 0.015). The group with ≥
101% increment of creatinine was also associated with
higher Liano scoring at the time of nephrology consulta-
tion (p < 0.001), including higher prevalence of hypoten-
sion (p < 0.001), oliguria (p < 0.001), jaundice (p =
0.008), coma (p = 0.027), and were on mechanical venti-
lation (p = 0.002). RIFLE classes reached during the ARF
were more severe in subjects in the ≥ 101% increment of
Table 1: Characteristics of patients, according to percentage of difference of creatinine* at nephrology consultation with respect to 
basal creatinine
GROUPS OF % CREATININE INCREASE
< 101% increment ≥ 101% increment p value
N of patients 323 323
Increase of Creatinine, median % (IQR). 34.07 (66.67) 201.52 (149.22)
Age, median years (IQR). 63 (20) 62 (17) 0.36
Male gender (%) 74.3 65.0 0.01
Surgical (%) 24.9 24.2 0.849
Oncology patients (%) 36.5 34.4 0.565
Patients with no previous history of CRF (%) 61.30 91.64 < 0.001
Basal Serum Creatinine according to the MDRD 1.04 (0.19) 1.04 (0.22) 0.25
equation, median (mg/dL) (IQR).
Patients with history of CRF (%) 38.70 8.36 < 0.001
Basal Serum Creatinine for CRF patients, median 2.3 (2.2) 1.5 (0.6) < 0.001
mg/dL (IQR),
RIFLE criteria (%) < 0.001
Risk 35.9 0.0
Injury 26.6 29.1
Failure 37.5 70.9
Basal Serum Albumin, median g/dL (IQR), 2.62 (1.07) 2.42 (0.86) 0.072
Basal Hemoglobin, median g/dL (IQR) 10.70 (3.10) 10.50 (3.20) 0.088
Community-acquired Acute Renal Failure (%) 36.0 46.6 0.020
Liano scoring, median (IQR) 0.23 (0.27) 0.30 (0.44) < 0.001
Karnofsky scoring, median (IQR) 70 (20) 60 (10) 0.015
Hypotension (%) 30.3 45.5 < 0.001
Oliguria (%) 31.3 50.8 < 0.001
Jaundice (%) 22.0 31.3 0.008
Coma (%) 11.8 18.0 0.027
Conciousness (%) 80.8 76.8 0.211
Mechanical ventilation (%) 18.3 28.5 0.002
Aminoglycoside use (%) 12.7 17 0.121
Radiocontrast procedures (%) 19.5 20.7 0.695
Diabetic (%) 11.1 6.5 0.037
Nephrotoxicity (%) 43.0 43.7 0.874
Causes of Acute Renal Failure 0.079
Pre-renal (%) 77.1 72.1
Intrinsic renal (%) 18.9 19.2
Post-renal (%) 2.2 3.4
Other causes (%) 1.9 5.3
Subsecuent Treatment of Acute Renal Failure < 0.001
Non-Dialytic (%) 75.5 61.0
Intermittent Hemodialysis (%) 7.1 7.7
Continuous Replacement Therapy (%) 11.1 22.6
Both (Intermittent+Continuous) (%) 6.2 8.7
Prior food intake 0.024
Optimal nutrition (%) 37 24
Light malnutrition (%) 18.1 20.7
Moderate malnutrition (%) 23.9 30.9
Severe malnutrition (%) 21 24.4
*Creatinine change (%) = [(creatinine at nephrology consultation - Basal creatinine)/Basal creatinine] × 100 IQR: Interquartile range. CRF: Chronic 
Renal Failure. MDRD: Modification of Diet in Renal DiseasePage 4 of 9
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lence of diabetes (p = 0.037) in this group.
The ≥ 101% increment group was associated with signifi-
cant increased total inhospital mortality (35.6% vs.
22.6%, P < 0.001), with an adjusted odds ratio of 1.81
(95% CI: 1.08–3.03) (Table 2). Moreover, those patients
in the ≥ 101% increment group who required continuous
renal replacement therapy presented a higher increase of
inhospital mortality (62.7% vs 46.4%, P = 0.048), with an
adjusted odds ratio of 2.66 (95% CI: 1.00–7.21) (Table
3). We noticed that patients in the ≥ 101% increment
group had a higher mean serum creatinine level in com-
parison to their baseline level (114.72% vs. 37.96%) at
hospital discharge (Table 4). In the ≥ 101% increment
group, creatinine was an adjusted 48.92% (95% CI:
13.05–84.79) higher than the < 101% increment group.
The overall mortality rate was 337 deaths (52.2%) in 6
months. According to the Kaplan-Meier plot, the ≥ 101%
increment group also had a statistically significant higher
mortality rate in this period as compared with the < 101%
increment group (Log Rank test = 0.012) (Figure 1). Dur-
ing the first 60 days of follow-up 175 deaths (27.1%)
occurred.
Discussion
This longitudinal study shows that a relative increase in
baseline serum creatinine by ≥ 101% compared with the
levels measured at the time of nephrology consultation is
an independent predictor of mortality. Such an increase
was also associated with worse functional renal recovery
irrespective of the degree of ARF severity or presence of
comorbid illnesses.
Due to the heterogeneous nature of ARF [11], it was
important to adjust for the severity of illness with Liano
score, and for the acute kidney injury with the RIFLE crite-
ria. We have chosen the Liano score because of its ability
to discriminate mortality from survival and its ability to
calibrate the observed mortality rate with the expected
mortality in ARF [11,14,27]. The RIFLE consensus criteria
gives a standard definition and a level of classification of
severity in ARF [20], a request often made by the experts
[6,18,19]. Working in this manner may allow continuing
further investigation in ARF, and is one of the main
strengths of this study. Patients did not do worse because
Table 3: Odds Ratio (ORs) and (95 % confidence intervals) for in-
hospital mortality; according to the increased percentage of 
creatinine* with respect to basal creatinine in patients who 
required Continuous Renal Replacement Therapy subsecuently
GROUPS OF % CREATININE 
INCREASE
< 101% 
increment
≥ 101% 
increment
p value
Creatinine and 
mortality
n 56 102
Incidence of in-
hospital mortality, n 
(%)
26 (46.4) 64 (62.7)
Odds Ratios
Crude OR (95% CI) 1.00 (Ref.) 1.94 (1.00 – 
3.76)
0.048
Age- and sex-adjusted 
OR (95% CI)
1.00 (Ref.) 2.01 (1.03 – 
3.92)
0.040
Multivariate-adjusted 
OR† (95% CI)
1.00 (Ref.) 2.66 (1.00 – 
7.21)
0.050
Additionally adjusted 
for Oncology patients
1.00 (Ref.) 2.88 (1.03 – 
8.09)
0.044
*Creatinine change (%) = [(creatinine at nephrology consultation - 
Basal creatinine)/Basal creatinine] × 100
†Adjusted for age, sex, Liano scoring, Karnofsky scoring, prior food 
intake, chronic renal failure, diabetes, treatment of acute renal failure, 
causes of acute renal failure, community-acquired acute renal failure, 
basal hemoglobin, basal serum albumin, and RIFLE classes.
Table 2: Odds Ratios (ORs) and (95% confidence intervals) for in-
hospital mortality; according to the increased percentage of 
creatinine with respect to basal creatinine*
GROUPS OF % CREATININE 
INCREASE
< 101% 
increment
≥ 101% 
increment
p value
Creatinine and 
mortality
n 323 323
Incidence of in-
hospital mortality, n 
(%)
73 (22.6) 115 (35.6)
Odds Ratios
Crude OR (95% CI) 1.00 (Ref.) 1.89 (1.34–
2.68)
< 0,001
Age- and sex-
adjusted OR (95% 
CI)
1.00 (Ref.) 1.91 (1.35–
2.70)
< 0,001
Multivariate-
adjusted OR† (95% 
CI)
1.00 (Ref.) 1.81 (1.08–
3.03)
0.024
Additionally adjusted 
for Oncology 
patients
1.00 (Ref.) 1.85 (1.09–
3.14)
0.023
* Creatinine change (%) = [(creatinine at nephrology consultation - 
Basal creatinine)/Basal creatinine] × 100
†Adjusted for age, sex, Liano scoring, Karnofsky scoring, prior food 
intake, chronic renal failure, diabetes, treatment of acute renal 
failure, causes of acute renal failure, community-acquired acute renal 
failure, basal hemoglobin, basal serum albumin, and RIFLE classes.Page 5 of 9
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patients presenting the same RIFLE criteria and Liano
scores, but with higher serum creatinine increments prior
to the nephrology consultation, showed higher mortality
rates.
Using multivariate logistic regression analysis, we found
that an increment in creatinine with respect to baseline
level of 101% at the time of nephrology consultation
started is a factor independently and strongly predictive of
death in this cohort. Doubling the basal creatinine level
presented an odds ratio of 1.81 for mortality among gen-
eral population. This increased to a threefold (OR = 2.66)
mortality in patients who needed continuous renal
replacement therapy. These results might suggest that the
increase of serum creatinine level at the moment when the
ARF began to be treated by an expert was related to the
outcome. However, we should concede the possibility
that the more abrupt increase in serum creatinine was, the
worse the prognosis. Because of the observational nature
of the present study, our findings need to be interpreted
with caution. We cannot determine with certainty that
finding a higher increase in the percentage of creatinine
was a consequence of a delayed nephrology consultation.
It could be that among patients who received the nephrol-
ogy intervention at the same time, some of them pre-
sented a higher increase in the percentage of creatinine
because of an abrupt deterioration of renal function. Nev-
ertheless, after adjusting for severity of ARF and comorbid
illnesses, patients who had had higher increments in per-
centage of creatinine prior to being treated by a nephrolo-
gist did present higher mortality rates. We might stand for
prompt expert consultation because these ARF patients at
risk would benefit from an intensive and specialized treat-
ment, and further kidney damage could be minimized.
The cohort included a heterogeneous distribution of
patients, in terms of unit, nature, or source of admission;
but with an important number of oncology patients
(35.4%) since our institution is a well-known center in
Spain for the treatment of oncologic diseases. For this rea-
son, we adjusted adding the oncology factor to the logistic
regression in an extra analysis. However, because of its
longitudinal design, we could obviate the Berkson bias (to
take a falsely typical population of patients since the
group of people being studied has no form of control over
whether to participate) [28]. Also, it could be argued that
this was a single center study, with its limits to apply to
other hospitals. We have tried to minimize any bias using
objetive data collected by a single investigator following
Table 4: Estimates (regression coefficients and 95% confidence 
intervals) for the subsequent outcome in % creatinine* (mg/dL) 
at discharge from hospital according to increased percentage of 
creatinine † with respect to basal creatinine
GROUPS OF % 
CREATININE INCREASE
< 101% 
increment
≥ 101% 
increment
p value
Creatinine
n 250 208
Absolute Creatinine 
change*
+37.96 +114.72
[%, mean (95% CI)] (29.46–46.47) (83.79–145.65)
Differences in 
Creatinine change
Crude 
(Regression 
coefficient, β)
0 (Ref.) +76.76 (+47.14 
to +106.38)
< 0.001
Age- sex-
adjusted
0 (Ref.) +71.27 (+41.78 
to +100.77)
< 0.001
(Regression 
coefficient, β)
Multivariate 
adjusted model‡
0 (Ref.) +48.92 (+13.05 
to +84.79)
0.008
(Regression 
coefficient, β)
Additionally 
adjusted for
0 (Ref.) +49.93 (+14.02 
to +85.83)
0.007
Oncology 
patients
*Creatinine change (%) = [(creatinine at nephrology discharge - Basal 
creatinine)/Basal creatinine] × 100
†Creatinine change (%) = [(creatinine at hospital consultation - Basal 
creatinine)/Basal creatinine] × 100
‡Adjusted for age, sex, Liano scoring, Karnofsky scoring, prior food 
intake, chronic renal failure, diabetes, treatment of acute renal failure, 
causes of acute renal failure, community-acquired acute renal failure, 
basal hemoglobin, basal serum albumin, and RIFLE classes.
Six-month survival after starting the nephrology consultation accordi g to increase creatin e percentage*Figu e 1
Six-month survival after starting the nephrology consultation 
according to increase creatinine percentage*.
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were not available; therefore it was not possible to esti-
mate the RIFLE criteria according to this value. We started
to collect the data before the RIFLE criteria was formu-
lated, and most of the ward patients had no urine output
measured on a six hourly basis. We assume that we might
underestimate some cases according to the RIFLE criteria;
but only 21 and 62 patients from groups R and I respec-
tively had oliguria. Although we cannot rule out the pos-
sibility of residual confounding, it is unlikely that it can
fully explain the observed strong associations. Moreover,
when we adjusted for RIFLE criteria, an increase of our
estimations occurred in the multivariate model; so mis-
classification of this covariate would most likely bias the
odds ratios toward the null value.
We calculated the MDRD equation to obtain a baseline
serum creatinine in patients with no previous history of
renal failure because a true baseline is often unknown. We
solved the equation assuming a GFR of 75 ml/minute/
1,73 m2, which has been reported to estimate a lower
limit of a normal GFR [4,13,20]. Because GFR was
assumed to be 75 ml/min, using MDRD for patients with
unknown pre-morbid renal dysfunction may underesti-
mate severity of ARF according to the RIFLE criteria
[29,30]. This lack of reliability is one of the controversial
issues regarding the RIFLE criteria, but it is still unresolved
[31]. Although the MDRD formula may be less accurate at
normal GFR, resulting in overdiagnosis of ARF, it should
not be a disadvantage in a clinical setting where ARF is
taken seriously, and the MDRD also has the advantage of
not requiring body weight data [32] that could be wrongly
estimated in fluid retention settings.
We chose to calculate the percentage change in creatinine
respect to its baseline because serum creatinine is modu-
lated by muscle bulk. Therefore, smaller changes as 0.3 or
0.5 mg/dL will have distinct significance for patients with
different genders and/or ages, whose normal baseline lev-
els are different [18]. For this reason, we found that a rel-
ative increase in creatinine was more accurate than an
absolute increase one.
The higher presence of chronic renal failure in the < 101%
increment group might be explained because concern
about it could have induced earlier nephrology consulta-
tion, even if the patient did not present signs of ARF in
that time. However, we must admit that 74 chronic renal
failure patients (48.68%) might have presented an unsta-
ble serum creatinine value at hospital admission, thus
underestimating the severity of ARF for them. Chronic
renal failure was included in this study to represent the
common clinical practice, and thereafter it was adjusted
for in the analysis because of expecting different outcomes
than the general population.
On the other hand, the higher proportion of cases of ARF
developed in the community in the ≥ 101% increase
group might suggest that nephrology consultation may
have been delayed because of time spent before hospital
admittance, giving serum creatinine an extra time to reach
a higher value.
Our results about mortality in the Renal Replacement
Therapy sub-group are consistent with previously
reported [9,33,34], and it is of interest the higher mortal-
ity rate in patients in the ≥ 101% increase group. What we
may learn here is that this group of patients is most likely
to benefit from a more intensive treatment.
The degree of renal injury is likely to affect renal recovery.
Patients where consultation was started with ≥ 101% cre-
atinine increase had significant higher creatinine levels at
discharge compared to their baseline levels, and many of
them would be expected to develop chronic renal mal-
function. Adjustment for confounding factors in the anal-
ysis was done, too.
We analyzed 6-months mortality separately, since the
time when patients are discharged from hospital might
vary between admission units. Although it could be
argued that all-cause mortality at six months is non spe-
cific, we found that a high number of deaths (175)
occurred in the first 60 days. These findings agree with
previous reports and recommendations about optimal
follow-up time in patients with established ARF
[20,26,35].
It is of interest to note that 306 patients from the original
population of 1008 would not have been diagnosed of
ARF had the RIFLE criteria been used then. They did not
present oliguria nor enough creatinine increment, but
were diagnosed of ARF according to another criteria at
that time. Some experts might prefer to use more inclusive
criteria because of concern about under-recognizing ARF
[6].
Finally, had our patients presented other mortality rates,
if they would have been treated by a nephrologist before
reaching serum creatinine levels more than twice their
baseline levels, is a question beyond this study and needs
further research.
Conclusion
At the same degree of severity of kidney injury and comor-
bid illnesses, while controlling for other potential con-
founders, ARF patients with a relative increase of ≥ 101%
in the baseline creatinine at the time of the nephrology
consultation was an independent predictor of mortality
and worse prognosis. The calculation of relative serum
creatinine increase could be used as a precise and usefulPage 7 of 9
(page number not for citation purposes)
BMC Nephrology 2007, 8:14 http://www.biomedcentral.com/1471-2369/8/14tool in the daily general medical practice, and may be an
effective tool to identify those patients who would benefit
from an intensive therapy. However, further investigation
about timing in nephrology consultation is needed to
provide robust knowledge about treatment and prognosis
in ARF.
Key messages
1. Acute renal failure is a condition with a high risk of
mortality.
2. At the same degree of acute renal failure and comorbid
illnesses severity, and receiving similar treatment, patients
who had presented an increment of creatinine ≥ 101%
with respect to baseline at the time of nephrology consul-
tation showed increased mortality rates.
3. Those patients were discharged from hospital with
more deteriorated renal function.
4. The calculation of relative serum creatinine increase
might be used as a precise and useful tool in the general
medical practice. Predicting the outcome helps to identify
those patients who would benefit from a intensive ther-
apy, and also to reassure patients and their relatives.
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